scholarly journals Efficacy and safety of immunosuppressive medications for steroid-resistant nephrotic syndrome in children: a systematic review and network meta-analysis

Oncotarget ◽  
2017 ◽  
Vol 8 (42) ◽  
pp. 73050-73062 ◽  
Author(s):  
Shaojun Li ◽  
Haiping Yang ◽  
Pengfei Guo ◽  
Xiaoxiao Ao ◽  
Junli Wan ◽  
...  
Keyword(s):  
Systematic Review ◽  
Nephrotic Syndrome ◽  
Meta Analysis ◽  
Efficacy And Safety ◽  
Steroid Resistant ◽  
Steroid Resistant Nephrotic Syndrome ◽  
Immunosuppressive Medications

scholarly journals Efficacy and safety of cyclosporine a for patients with steroid-resistant nephrotic syndrome: a meta-analysis

2019 ◽  
Vol 20 (1) ◽  
Author(s):  
Hong-Yan Li ◽  
Xialan Zhang ◽  
Tianbiao Zhou ◽  
Zhiqing Zhong ◽  
Hongzhen Zhong
Keyword(s):  
Nephrotic Syndrome ◽  
Serum Creatinine ◽  
Cyclosporine A ◽  
Plasma Cholesterol ◽  
Meta Analysis ◽  
Cochrane Library ◽  
Efficacy And Safety ◽  
Steroid Resistant ◽  
Steroid Resistant Nephrotic Syndrome ◽  
The Cochrane Library

Abstract Background The purpose of this study was to determine efficacy and safety of cyclosporine A (CsA) for patients with steroid-resistant nephrotic syndrome (SRNS). Methods The Cochrane Library and PubMed were searched to extract the associated studies on Oct 10, 2018, and the meta-analysis method was used to pool and analyze the applicable investigations included in this study. The P(opulation) I(ntervention) C(omparison) O(utcome) of the study were defined as follows: P: Patients with SRNS; I: treated with CsA, cyclophosphamide (CYC), tacrolimus (TAC) or placebo/not treatment (P/NT); C: CsA vs. placebo/nontreatment (P/NT), CsA vs. CYC, CsA vs. TAC; O: complete remission (CR), total remission (TR; complete or partial remission (PR)), urine erythrocyte number, proteinuria levels, albumin, proteinuria, serum creatinine, and plasma cholesterol, etc. Data were extracted and pooled using RevMan 5.3. Results In the therapeutic regimen of CsA vs. placebo/nontreatment (P/NT), the results indicated that the CsA group had high values of CR, TR, and low values of proteinuria, serum creatinine, and plasma cholesterol when compared with those in the placebo group. In comparing CsA vs. cyclophosphamide (CYC), the results indicated that the CsA group had higher TR than the CYC group. In comparing CsA vs. tacrolimus (TAC), the results revealed insignificant differences in CR, and TR between the CsA and TAC groups. The safety of CsA was also assessed. The incidence of gum hyperplasia in CsA group was higher than that in the P/NT group, with no differences in incidence of infections or hypertension between CsA and P/NT groups. There was no difference in the incidence of hypertension between the CsA and TAC groups. Conclusions CsA is an effective and safe agent in the therapy of patients with SRNS.

Rituximab in The Management of Pediatric Steroid-Resistant Nephrotic Syndrome: A Systematic Review

2018 ◽  
Vol 197 ◽  
pp. 191-197.e1 ◽  
Author(s):  
Manel Jellouli ◽  
Rim Charfi ◽  
Bayen Maalej ◽  
Abdelmajid Mahfoud ◽  
Sameh Trabelsi ◽  
...  
Keyword(s):  
Systematic Review ◽  
Nephrotic Syndrome ◽  
Steroid Resistant ◽  
Steroid Resistant Nephrotic Syndrome

Interventions for steroid-resistant nephrotic syndrome: a systematic review

2003 ◽  
Vol 18 (9) ◽  
pp. 906-912 ◽  
Author(s):  
Doaa Habashy ◽  
Elisabeth M. Hodson ◽  
Jonathan C. Craig
Keyword(s):  
Systematic Review ◽  
Nephrotic Syndrome ◽  
Steroid Resistant ◽  
Steroid Resistant Nephrotic Syndrome
Sign in / Sign up

Export Citation Format

Share Document